Systematic Review and Meta-analysis on the Effect of Soy on Thyroid Function

Jemiliat Otun, Amirhossein Sahebkar, Linda Östlundh, Stephen L. Atkin & Thozhukat Sathyapalan

Soy foods have had an important dietary role in Asian countries for centuries, and in recent years they have become increasingly popular in Western countries as a result of their suggested health benefits. Nevertheless, there are some concerns that soy can have a negative effect on thyroid function and can alter the levels of thyroid hormones. The aim of this systematic review was to investigate the link between soy or soy product consumption and thyroid function via the measurement of thyroid hormone levels. A systematic review and meta-analysis was undertaken on all randomised controlled trials of studies including soy as an intervention and where free triiodothyronine (fT3), free thyroxine (fT4) and thyroid stimulating hormone (TSH) was measured. The search included PubMed, MEDLINE, EMBASE, Cochrane and sources for the grey literature. Quantitative data synthesis was performed using a random-effects model, with standardized mean difference (SMD) and 95% confidence interval as summary statistics. A total of 18 articles were suitable for review. The meta-analysis showed no significant changes in fT3 (WMD: 0.027 pmol/L, 95% CI: −0.052, 0.107, \( p = 0.499; I^2: 55.58\%\)), fT4 (WMD: −0.003 pmol/L, 95% CI: −0.018, 0.011, \( p = 0.656; I^2: 87.58\%\)) while an elevation in TSH levels was observed (WMD: 0.248 mIU/L, 95% CI: 0.001, 0.494, \( p = 0.049; I^2: 80.31\%\)) levels with soy supplementation. There was no evidence of publication bias. Soy supplementation has no effect on the thyroid hormones and only very modestly raises TSH levels, the clinical significance, if any, of the rise in TSH is unclear.

Soy has been a staple in the diet in South and East Asian countries for many years and has become popular in Western countries as a result of the suggested health benefits that include protection against osteoporosis, cardiovascular diseases, diabetes, breast cancer and prostate cancer.

The two main components of soy thought to be responsible for the proposed health benefits are soy protein and the soy isoflavones. It is believed that isoflavones present in soy are the main active compounds that produce both hormonal and non-hormonal effects. Isoflavones are a subclass of common plant compounds called flavonoids. They usually exist in food as biological inactive forms, such as genistin and daizin, which are present in soy as β-D-glycosides. These glycosides can be hydrolyzed and deconjugated by β-glycosidases synthesized by intestinal bacteria to form biologically active aglycone forms of isoflavones, such as genistein and daidzein. Public interest in the health benefits of soy isoflavones has led to the development of isoflavone supplements and the fortification of foods with isoflavones.

However, there is speculation that for certain subsets of the population soy foods and isoflavones may be detrimental. Concern has been expressed that soy may adversely affect thyroid function in susceptible individuals by interfering with the absorption of synthetic thyroid hormone. Although the anti-thyroid effect of soy has been investigated in animals for decades, the identification of several cases of thyroid enlargement in infants consuming soy formula in the early 1960s, over 60 years ago, became apparent. It has been shown that isoflavones inhibit the activity of thyroid peroxidase (TPO), an enzyme involved in the synthesis of triiodothyronine (T3) and thyroxine (T4), in vivo in rats and in vitro.
There is some evidence to suggest that soy consumption is associated with thyroid disorders such as hypothyroidism, goitre, and autoimmune thyroid disease. The potential public health implications of the possible anti-thyroid effects of soy is important since as many as 10% of postmenopausal women, for whom soy foods have particular appeal, may be hypothyroid, and a large proportion of these may be undiagnosed. Thus, it is crucial to clarify the relationship between soy and thyroid function. There was a review of literature on the effect of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients in 2006, although this was not a prospectively registered systematic review. In 2015, the European Food Safety Authority (EFSA) conducted a risk assessment that included the effect of soy protein and soy isoflavones on thyroid function, however, there have been a number of randomised controlled studies published after this review. The EFSA concluded soy isoflavones were without effect on thyroid function.

Material and Methods

Search Strategy. A comprehensive, systematic search for information was conducted in several academic databases as well as in sources of grey literature based on following the main search string:

(TSH OR thyrotropin OR triiodothyronine OR thyroxine OR "Iodide peroxidase" OR "TPO protein" OR "TPO proteins" OR thyroid* OR T4 OR T3) OR hypothyroid* OR levothyroxine) AND (equol OR phytoestrogen* OR genistein OR daidzein OR glycitein OR soy* OR genistin OR "lipofundin s" OR "sodium-iodide symporter" OR GCP OR isoflavones).

Pre-searches to identify relevant search terms, search strategies and information sources were conducted in May–June 2016, and the main search was carried out in July–August 2016. Additional searches for grey literature were later conducted during August–September 2016.

PubMed was used to systematically develop and test the search string, which later was adapted and applied to MEDLINE (WOS), EMBASE (OVID), and Cochrane.

All terms were searched in the fields “Abstract” and “Article Title” and in MeSH/Subject Headings/Thesaurus when available. No filters or limitations were applied in order to retrieve the best possible result and to avoid excluding pre-indexed materials.

All references were uploaded to the reference management software EndNote and transferred to the systematic review software Covidence for de-duplication, screening and data extraction.

In addition to the search in academic databases, ProQuest Dissertation and Thesis, Ethos, Open Grey, The New York Academy of Grey Literature Reports and Clinical Trials were searched for grey materials. The sources were selected based on pre-searches and includes American, European as well as global publications. Due to the lack of advanced search features in many of the grey resources, broader search strings than the one used in the academic databases had to be applied.
An updated search in PubMed with a publication filter for the period August 2016–August 2018 was additionally conducted in August 2018 to include the most recent papers published.

**Study Selection.** Original studies were included if they met the following inclusion criteria: (i) Adult trials, (ii) being a randomized controlled trial with either parallel or cross-over design, (iii) investigating the impact of soy products e.g. isoflavones, genistein and/or daizein on plasma/serum concentrations of TSH, fT3 and fT4, and (iv) presentation of sufficient information on TSH, fT3 and fT4 concentrations at baseline and at the end of follow-up in each group or providing the net change values. Exclusion criteria were: (i) Animal trials, (ii) Child/
Adolescent Trials (iii) observational studies with case-control, cross-sectional or cohort design, and (iv) lack of sufficient information on baseline or follow-up TSH, fT3 and fT4 concentrations.

**Data extraction.** Eligible studies were reviewed and the following data were abstracted by two co-authors. Any disagreements were resolved through discussion and consultation with a third co-author: (1) first author’s name; (2) year of publication; (3) country where the study was performed; (4) study design; (5) number of participants in the intervention and control/placebo groups; (6) intervention assigned to the control group if any; (7) soy product type (isoflavones, genistein and/or daidzein) and dose of soy supplement; (8) treatment duration; (9) age, gender and body mass index (BMI) of study participants; and (9) data regarding baseline and follow-up plasma concentrations of TSH, fT3 and fT4.

**Quantitative Data Synthesis.** Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software (Borenstein M et al. Comprehensive Meta-analysis Version 2, Biostat, Englewood NJ, 2005). A random-effects model (using DerSimonian-Laird method) and the generic inverse variance weighting method were used to compensate for the heterogeneity of studies in terms of study design, treatment duration, and the characteristics of populations being studied. Standard deviations (SDs) of the mean difference were calculated using the following formula: $SD = \sqrt{(SD_{pre-treatment})^2 + (SD_{post-treatment})^2 - (2 \times \text{SD}_{pre-treatment} \times \text{SD}_{post-treatment})}$, assuming a correlation coefficient (R) = 0.5. Where standard error of the mean (SEM) was only
The results showed the robustness of the pooled estimate with different R values. Meta-analysis, sensitivity analyses were performed by repeating the analysis with R values of 0.2, 0.3, 0.7 and 0.8. A conservative estimate for R which ranges between 0 and 1. In order to check if the R value can alter the results of the meta-analysis, sensitivity analyses were performed by repeating the analysis with R values of 0.2, 0.3, 0.7 and 0.8. The results showed the robustness of the pooled estimate with different R values.

Publication bias. Evaluation of funnel plot, Begg’s rank correlation and Egger’s weighted regression tests were employed to assess the presence of publication bias in the meta-analysis. When there was evidence of funnel plot asymmetry, potentially missing studies were imputed using the “trim and fill” method. This method imputes the potentially missing studies on either side of the funnel plot, and then re-computes the effect size considering inclusion of potentially missing studies.

Results

4925 references were found through the literature search, with 1816 references remaining after de-duplication. Additionally, 145 papers were identified in the updated PubMed search and hand screened. A total of 4 new papers were selected to be included in the study. A full search log, including search string, results and notes can be found in Appendix 1.

In total, after the initial and updated searches, 84 references were identified in the TI/AB screening, 23 were remaining after full text screening and a final of 18 selected to be included in the meta-analysis. A PRISMA flow diagram of the screening and selection process can be found in Fig. 1.

The interventions used in the studies were mainly food supplements containing soy isoflavones, soy extract, soy protein, daidzein-rich isoflavones and genistein alone. The doses used in the studies ranged from 40–200 mg/day. In comparison, in one survey based study older Japanese adults consumes approximately 25–50 mg of isoflavones (expressed as aglycone equivalents) per day. We included only fT3 and fT4 since they are the metabolically active form of thyroid hormones since they are not bound to plasma proteins including thyroid binding globulin.

Since the primary endpoints in most studies included were not related to thyroid function except seven studies, the sample sizes were mainly determined on the basis of expected changes in other endpoints. Data from 18 studies were included in the meta-analysis. Out of this, two studies included both men and women, whilst the other studies included only women. Two studies looked into changes in thyroid function in patients with subclinical hypothyroidism.

Quantitative data synthesis. Meta-analysis of data from 21 and 22 treatment arms did not reveal any significant effect of soy product consumption on fT3 (WMD: 0.027 pmol/L, 95% CI: −0.052, 0.107, p = 0.499; I²: 55.58%) and fT4 (WMD: −0.003 pmol/L, 95% CI: −0.018, 0.011, p = 0.656; I²: 87.58%). However, analysis of 26 treatment arms revealed a significant elevation in TSH levels following soy product consumption (WMD: 0.248 mIU/L, 95% CI: 0.001, 0.494, p = 0.049; I²: 80.31%) (Fig. 2). Iterative removal of included study arms from the meta-analysis did not reveal sensitivity of the pooled effect size estimate to any single treatment arm in the meta-analyses of fT3 and fT4. However, the meta-analysis of TSH was sensitive to one of the included treatment arms (Fig. 3).

We have performed subgroup analysis of TSH for potential confounding factors and sources of heterogeneity between studies which included gender, menopause status, health status at baseline, treatment duration and presence of subclinical hypothyroidism at baseline (Table 1).

|                     | WMD (95% CI) | p-Value | Between group p-value |
|---------------------|--------------|---------|-----------------------|
| Gender              |              |         |                       |
| Male                | 0.004 (−0.191, 0.199) | 0.968    | 0.004                 |
| Female              | 0.232 (−0.087, 0.552)  | 0.154    |                       |
| Menopausal status   |              |         |                       |
| Premenopausal       | 0.020 (−0.565, 0.606)  | 0.946    | 0.580                 |
| Postmenopausal      | 0.184 (−0.098, 0.466)  | 0.201    |                       |
| Health status at baseline |          |         |                       |
| Healthy             | 0.131 (−0.108, 0.371)  | 0.282    | 0.121                 |
| Not healthy         | 0.493 (0.104, 0.883)   | 0.013    |                       |
| Treatment duration  |              |         |                       |
| <3 months           | 0.006 (−0.180, 0.191)  | 0.952    |                       |
| ≥3 months           | 0.319 (0.034, 0.604)   | 0.028    | 0.710                 |
| Subclinical hypothyroidism at baseline |         |         |                       |
| Yes                 | 0.692 (0.333, 1.052)   | <0.001   | 0.032                 |
| No                  | 0.199 (−0.074, 0.472)  | 0.154    |                       |

Table 1. Subgroup analysis for changes in TSH.
Subgroup analysis of changes in TSH reveals treatment duration of more than or equal to three months (WMD (95% CI) 0.319 (0.034, 0.604; p value 0.028) and presence of subclinical hypothyroidism at baseline (WMD (95% CI) 0.692 (0.333, 1.052; p value < 0.001) were significant.

Publication bias. Visual inspection of Begg’s funnel plots revealed asymmetry in the meta-analyses of soy product’s effects on fT3, fT4 and TSH levels. Using trim and fill correction, 3, 2 and 6 potentially missing studies were imputed (Fig. 4). Imputed effect sizes and the results of Begg’s rank correlation and Egger’s regression tests are summarized in Table 2.

Table 2. Imputed effect sizes and the results of Begg’s rank correlation and Egger’s regression tests for the meta-analysis of Soy’s effects on thyroid hormones. aThe number of imputed studies according to the trim and fill correction method; bBegg’s rank correlation test; cEgger’s weighted regression test.

|     | n  | WMD | 95% CI        | P-valuea | P-valuec |
|-----|----|-----|--------------|----------|----------|
| fT3 | 3  | 0.068 | −0.012, 0.148| 0.381    | 0.374    |
| fT4 | 2  | −0.003 | −0.018, 0.011| 0.338    | 0.224    |
| TSH | 6  | 0.358 | 0.139, 0.577 | 0.067    | 0.065    |

Figure 4. Funnel plot detailing publication bias in the studies reporting the impact of soy products on fT3, fT4 and TSH levels.
Discussion

This systematic review showed that there was a significant change in TSH as a result of soy protein and/or isoflavones supplementation though with no significant changes in fT3 and fT4 levels suggesting that whilst soy can adversely affect thyroid function, clinically this may not be significant. This is the converse reported from the EFSA risk assessment on 2015 that did not show that food supplements containing isolated isoflavones caused any significant effects on thyroid function in peri- or post-menopausal women17; however, new randomised controlled trials have been published since this report.

A study that examined the effect of soy isoflavones in patients with type 2 diabetes and hypogonadism showed a significant increase in TSH and reduction in fT4 with 12 weeks of combined soy protein and isoflavone supplementation, though none developed subclinical or overt hypothyroidism36. Another study published recently comparing soy protein and casein protein without soy isoflavones in patients with subclinical hypothyroidism reported no significant changes in thyroid function19.

In one of the studies in patients with subclinical hypothyroidism comparing the effect of low dose phytoestrogen (2 mg comparable to Western diet) with higher dose phytoestrogen (comparable to a vegetarian diet), there were no significant changes in thyroid function test as a group. However, of the 60 patients, six of the 52 female subjects (11.5%) progressed into overt hypothyroidism after the 16-mg isoflavone arm of the 6-month period showing a 3-fold increase (standardized rate ratio of 3.6 (95% confidence interval = 1.9, 6.2)) in progression from subclinical to overt hypothyroidism20.

Soy containing food products have been potentially implicated in deterioration of thyroid function. Goitre has been seen in infants fed soy formula; this is usually reversed by changing to cows’ milk or iodine-supplemented diets12,13. In vitro research14,15 and studies in rodents16 supplemented with isolated isoflavones suggests that soy can have an anti-thyroid effect. There are concerns that they may compromise thyroid function14,17, an issue for patients with subclinical or overt hypothyroidism, particularly during pregnancy18–20.

In conclusion, this meta-analysis suggests that soy supplementation has no effect on the thyroid hormones and modestly raises TSH levels, the clinical significance, if any, of the rise in TSH is unclear.

References

1. Messina, M., Ho, S. & Alekel, D. L. Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr Opin Clin Nutr Metab Care 7, 649–658 (2004).
2. Gil-Izquierdo, A. et al. Soy isoflavones and cardiovascular disease epidemiological, clinical and -omics perspectives. Curr Pharm Biotechnol 13, 624–631 (2012).
3. Jayagopal, V. et al. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 25, 1709–1714 (2002).
4. Cederroth, C. R. & Nef, S. Soy, phytoestrogens and metabolism: A review. Mol Cell Endocrinol 304, 30–42, https://doi.org/10.1016/j.mce.2009.02.027 (2009).
5. Kang, X., Zhang, Q., Wang, S., Huang, X. & Jin, S. Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ 182, 1857–1862, https://doi.org/10.1503/cmaj.091288 (2010).
6. Hwang, Y. W., Kim, S. Y., Jee, S. H., Kim, Y. N. & Nam, C. M. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer 61, 598–606, https://doi.org/10.1080/01635580902825639 (2009).
7. Setchell, K. D. Soy isoflavones–benefits and risks from nature’s selective estrogen receptor modulators (SERMs). J Am Coll Nutr 20, 354S–362S; discussion 381S–383S (2001).
8. Nurmia, T., Mazur, W., Heinonen, S., Kekkonen, J. & Adlercreutz, H. Isoflavone content of the soy based supplements. Journal of pharmaceutical and biomedical analysis 28, 1–11 (2002).
9. Doerge, D. R. & Sheehan, D. M. Goitrogenic and estrogenic activity of soy isoflavones. Environ Health Perspect 110(Suppl 3), 349–353 (2002).
10. Bell, D. S. & Ovalle, F. Use of soy protein supplement and resultant need for increased dose of levothyroxine. Endocr Pract 7, 193–194, https://doi.org/10.4158/EP7.3.193 (2001).
11. McCarrison, R. A Paper on FOOD AND GOITRE. Br Med J 2, 671–675 (1933).
12. Hydovitz, J. D. Occurrence of goiter in an infant on a soy diet. N Engl J Med 262, 351–353, https://doi.org/10.1056/NEJM196002182620707 (1960).
13. Chang, H. C. & Doerge, D. R. Dietary genistein inactivates rat thyroid peroxidase in vivo without an apparent hypothyroid effect. Toxicol Appl Pharmacol 168, 244–252, https://doi.org/10.1016/j.taap.2000.09.019 (2000).
14. Divi, R. L., Chang, H. C. & Doerge, D. R. Anti-thyroid isoflavones from soybean: isolation, characterization, and mechanisms of action. Biochem Pharmacol 54, 1087–1096 (1997).
41. Wilgrus, H. S. J., Gassner, F. X., Patton, A. R. & Gustavson, R. G. The goitrogenicity of soyabeans.

43. Canaris, G. J., Manowitz, N. R., Mayor, G. & Ridgway, E. C. The Colorado thyroid disease prevalence study.

44. Haddow, J. E.

39. Divi, R. L. & Doerge, D. R. Inhibition of thyroid peroxidase by dietary flavonoids.

36. Sathyapalan, T.

34. Duncan, A. M.

27. Bitto, A.

28. Yim, C. H.

29. Khaodhiar, L.

31. Persky, V. W.

33. Tousen, Y.

23. Messina, M., Nagata, C. & Wu, A. H. Estimated Asian adult soy protein and isoflavone intakes.

18. Sathyapalan, T.

19. Sathyapalan, T., Javed, Z., Rigby, A. S., Kilpatrick, E. S. & Atkin, S. L. Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-blind Crossover Study. J Endocr Soc 1, 423–430, https://doi.org/10.1210/js.2016-1068 (2017).

20. Sathyapalan, T.

16. Messina, M. & Redmond, G. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 16, 249–258, https://doi.org/10.1089/thy.2006.16.249 (2006).

15. Mazer, N. A. Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women. Thyroid 14(Suppl 1), S27–34, https://doi.org/10.1089/10507259403320426 (2004).

17. EFSA. Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones. EFSA Journal (2015).

19. Sathyapalan, T., Javed, Z., Rigby, A. S., Kilpatrick, E. S. & Atkin, S. L. Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-blind Crossover Study. J Endocr Soc 1, 423–430, https://doi.org/10.1210/js.2016-1068 (2017).

20. Sathyapalan, T.

16. Messina, M. & Redmond, G. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 16, 249–258, https://doi.org/10.1089/thy.2006.16.249 (2006).

15. Mazer, N. A. Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women. Thyroid 14(Suppl 1), S27–34, https://doi.org/10.1089/10507259403320426 (2004).

17. EFSA. Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones. EFSA Journal (2015).

19. Sathyapalan, T., Javed, Z., Rigby, A. S., Kilpatrick, E. S. & Atkin, S. L. Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-blind Crossover Study. J Endocr Soc 1, 423–430, https://doi.org/10.1210/js.2016-1068 (2017).

20. Sathyapalan, T.

16. Messina, M. & Redmond, G. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 16, 249–258, https://doi.org/10.1089/thy.2006.16.249 (2006).

15. Mazer, N. A. Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women. Thyroid 14(Suppl 1), S27–34, https://doi.org/10.1089/10507259403320426 (2004).

17. EFSA. Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones. EFSA Journal (2015).

19. Sathyapalan, T., Javed, Z., Rigby, A. S., Kilpatrick, E. S. & Atkin, S. L. Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-blind Crossover Study. J Endocr Soc 1, 423–430, https://doi.org/10.1210/js.2016-1068 (2017).

20. Sathyapalan, T.

16. Messina, M. & Redmond, G. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 16, 249–258, https://doi.org/10.1089/thy.2006.16.249 (2006).

15. Mazer, N. A. Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women. Thyroid 14(Suppl 1), S27–34, https://doi.org/10.1089/10507259403320426 (2004).
